Efficacy and Safety of Abelmoschus Manihot for Chronic Kidney Disease
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 1600 participants.
Also called NCT02231138
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 1,600 participants
- Sponsor
- Registry
-
NCT02231138
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT02231138. Allocation not applicable; no masking; primary purpose treatment. Start 2014-09 (registry gives no type); primary completion 2016-01 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Abelmoschus Manihot for Chronic Kidney Disease
- Condition
- Chronic Kidney Disease
- Intervention (Drug)
- Abelmoschus manihot (AM)
- Lead sponsor
- Chinese PLA General Hospital
- Collaborator
- Jiangsu Suzhong Pharmaceutical Group Co., Ltd.
Record details
- Record id
cardio:ct-nct02231138- Content hash
9ac705e6447d0930f264dd8bd970efa31529d232cd22e31524af33fda33d037e